抑制耐药型 CAR 用于 NK 细胞癌症免疫疗法。
Inhibition-Resistant CARs for NK Cell Cancer Immunotherapy.
机构信息
Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20892, USA.
Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20892, USA.
出版信息
Trends Immunol. 2019 Dec;40(12):1078-1081. doi: 10.1016/j.it.2019.10.004. Epub 2019 Nov 12.
The promise of natural killer (NK) cells as effectors in cancer cellular therapy is limited by their expression of dominant inhibitory receptors for human leukocyte antigen (HLA) class I. Here, we discuss how chimeric antigen receptors (CARs) engineered to override inhibitory signaling might boost NK cell antitumor responses, independently of blockade of NK cell inhibitory receptors.
自然杀伤 (NK) 细胞作为癌症细胞治疗效应物的前景受到其对人类白细胞抗原 (HLA) 类 I 表达的主要抑制性受体的限制。在这里，我们讨论了如何设计嵌合抗原受体 (CAR) 以克服抑制性信号，从而增强 NK 细胞的抗肿瘤反应，而不依赖于阻断 NK 细胞抑制性受体。
Zotero 插件